01801 INNOVENT BIOWatchlist
About INNOVENT BIO Company
Cinda Biopharmaceuticals is a biopharmaceutical company dedicated to developing, manufacturing and selling high-quality innovative drugs that ordinary people can afford to use. The company was founded by Dr. Yu Dechao in 2011 and has built a multi-functional fully integrated biopharmaceutical platform that meets global quality standards, integrating R&D, clinical development, CMC and commercialization capabilities. The company has established a rich product pipeline, covering a series of innovative therapeutic targets and drug forms (including monoclonal antibodies, multi-specific antibodies, immune cytokines, fusion proteins, T-cell conjugators, antibody-conjugated drugs, cell therapy, small molecule drugs, etc.), covering various major disease fields such as oncology, cardiovascular and metabolic, immunology, and ophthalmology. The product pipeline has huge clinical and commercial potential as a single drug or combination therapy to meet a broad range of medical needs. The company has reached 30 strategic collaborations with international partners such as Eli Lilly, Roche Group, Sanofi, Adimab, Incyte, and the University of Texas Anderson Cancer Center. The company hopes to work with everyone to promote the development of the biopharmaceutical industry, improve the accessibility of medicines and the quality of life for patients.
Changes in Hong Kong stocks | Cinda Biotech (01801) rose nearly 4%; IBI351's new drug marketing application was officially accepted by the State Drug Administration and included in priority review
Cinda Biotech (01801) rose nearly 4%. As of press release, it was up 3.54% to HK$45.3, with a turnover of HK$361 million.
[Broker Focus] CITIC Construction Investment maintains Cinda Biotech's (01801) “buy” rating, and the company is expected to usher in a new round of growth in the future
According to the CITIC Construction Investment Research Report, Cinda Biotech (01801) has deployed a variety of excellent products on the oncology circuit, covering a wide range of patients. As ROS1 TKI and KRAS G12C TKI both submit listing applications, the company's oncology pipeline is expected to be strengthened and overall sales will experience further growth.
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali
UOBKH: Healthcare – China (Overweight) - Alpha Edge Investing
$WUXI BIO(02269.HK)$$WUXI APPTEC(02359.HK)$$INNOVENT BIO(01801.HK)$$VENUS MEDTECH-B(02500.HK)$$HENLIUS(02696.HK)$$Aier Eye Hospital Group(300015.SZ)$$Shenzhen Mindray Bio-Medical Electronics(300760.SZ)$
There was HKD203.3 million, HKD111.8 million and HKD106.6 million Southbound Trading net outflow from $TENCENT(00700.HK)$ , $HAITONG INT'L(00665.HK)$ and $XPENG-W(09868.HK)$ .
For $SH->HK Connect(GangGuTong.HK)$ , $MEITUAN-W(03690.HK)$ was the most active sto...
For $SH->HK Connect(GangGuTong.HK)$ , $TRACKER FUND OF HONG KONG(02800.HK)$ was the most active stock with highest net inflow of HKD1.7 billion, while $SUNAC(01918.HK)$ was the most active stock with highest net outflow of HKD16.9 million.
For $SZ->HK Connect(BK1922.HK)$...